A short-acting GLP-1 receptor agonist used in type 2 diabetes, best known as Adlyxin and as a component of Soliqua 100/33.
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist designed to mimic the body’s own incretin signaling after meals. By activating GLP-1 receptors, it increases glucose-dependent insulin secretion, suppresses glucagon, and slows gastric emptying. That last effect is important: lixisenatide is a short-acting GLP-1, so its strongest impact is on post-meal glucose spikes rather than all-day appetite suppression.
In the US, lixisenatide was approved as Adlyxin for adults with type 2 diabetes and later became a fixed-ratio ingredient in Soliqua 100/33 with insulin glargine. That makes it clinically relevant even though many clinics now favor longer-acting GLP-1s for broader metabolic goals. Lixisenatide is still a real, legitimate prescription peptide — not a gray-market “research” product.
Because it is short-acting, lixisenatide tends to be discussed in diabetes care more than in weight-loss marketing. If a clinic is pitching it as a generic anti-aging or fat-burning shortcut, that’s a signal to slow down and ask better questions.
The ELIXA trial evaluated lixisenatide in people with type 2 diabetes who had recently experienced an acute coronary syndrome. The headline finding was cardiovascular safety — it did not increase major cardiovascular events — but it did not show the kind of large cardiovascular benefit later seen with some other GLP-1s. In practice, that helps explain why newer agents often get more attention when the goal is weight loss or cardiometabolic risk reduction.
Clinically, lixisenatide has a strong role in improving postprandial glucose, especially when paired with basal insulin in Soliqua 100/33. It is less commonly used than semaglutide or tirzepatide because it is daily rather than weekly and because the evidence base for weight reduction is narrower.
📚 Key Reference: PMID: 26630143 (ELIXA), PMID: 33068776 (GLP-1 review)
Common side effects include nausea, vomiting, diarrhea, and reduced appetite, especially early in treatment. Because lixisenatide can slow gastric emptying, it may also affect how quickly other oral medicines are absorbed. More serious risks include pancreatitis and dehydration-related kidney injury if vomiting or poor intake leads to volume depletion.
Hypoglycemia is uncommon when lixisenatide is used alone, but risk rises when it is paired with insulin or sulfonylureas. It is not for type 1 diabetes or diabetic ketoacidosis. If a patient already uses another GLP-1 receptor agonist, duplication is usually a red flag rather than a plan.
Lixisenatide is FDA-approved in the US and is not a novelty peptide. It has been marketed as Adlyxin and is also part of Soliqua 100/33, a fixed-ratio product paired with insulin glargine. That means the right question is usually not “is it real?” but “why is this being chosen for this patient instead of a more established GLP-1 strategy?”